Trastuzumab pamirtecan
- Generic Name
- Trastuzumab pamirtecan
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Phase 1
Recruiting
- Conditions
- Advanced Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2025-02-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 320
- Registration Number
- NCT06827236
- Locations
- 🇺🇸
Hematology - Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, United States
🇲🇩Institute of Oncology Arensia Exploratory Medicine, Chisinau, Moldova, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath